WESTWOOD PHARMACEUTICALS' PRESUN SPF 29 UVA/UVB SUNSCREEN "offers [the] highest waterproof protection in a non-PABA formula," the company asserted in a Feb. 10 press release announcing the sunscreen's launch. PreSun 29 Sensitive Skin Sunscreen, which began shipping to retailers in January, is Westwood's first sunscreen to claim an SPF of over 15. "Unlike many older formulations of sunscreen with a maximum SPF of 15, which still allowed for some sun damage in highly sun-sensitive people, PreSun 29 offers maximum protection from both UVA and UVB sun rays," the Bristol-Myers subsidiary maintained. PreSun 29 is being promoted as a product that "provides 29 times your natural sunburn protection and may help reduce the chance of premature aging and wrinkling of the skin as well as skin cancer cause by overexposure to the sun." Westwood recommends daily use and is offering PreSun formulas in SPFs of 4, 8 and 15. The sunscreen "contains the most effective UVA absorbing ingredient available today," Westwood claims. The product's active ingredients are octyl methoxycinnamate, oxybenzone and octyl salicylate. The active ingredients are contained in a patentable polymer system developed by Westwood. The formulation provides for uniform application of the product and prevents beading when exposed to water, Westwood said. The non-greasy formula also "maintains its SPF 29 even after 80 minutes in the water." A 4 oz. bottle of PreSun 29 will retail for under $6. Westwood said it will support the launch with consumer and medical print ads, free-standing inserts and in-season TV. The product features an on-pack offer of up to $1.50: a 50› coupon and a $1 mail-in refund. With the new launch, Westwood joins a growing number of companies marketing non-PABA, high SPF sunscreens including Neutrogena and Schering-Plough, with its Coppertone Water Babies products.
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
If US tariffs on pharmaceutical supply chain products come into force they could be disruptive for companies. Ewan Townsend, of the international law firm Arnold & Porter, explains how companies can mitigate issues through negotiating with suppliers and reallocating tariff responsibilities.
With European biosimilars developers buoyed by recent regulatory moves, Medicines for Europe’s Isabell Remus and Julie Maréchal-Jamil discuss the next steps forward for the industry.
